Hagerty is a monopolistic, highly profitable tollbooth on the multi-billion-dollar collector car ecosystem with compounding structural growth, though investors must vigilantly monitor underwriting volatility as the firm transitions to retaining 100% of its insurance risk.
Warrior Met Coal is entering a period of explosive, high-visibility cash flow generation driven by its world-class Blue Creek expansion, but elevated trailing multiples and severe insider selling warrant caution regarding the durability of the global steel pricing cycle.
Howard Hughes is transforming into a dominant, Berkshire-style compounding machine by leveraging cash-gushing real estate monopolies to fund a high-yielding insurance float, trading at a massive, unwarranted discount to its intrinsic net asset value.
Hamilton Lane operates as the premier, indispensable toll-collector of the expanding private markets ecosystem, trading at an undeniable cash-flow discount despite boasting 30%+ ROE, though investors must navigate the cyclical lumpiness of its massive, yet macro-dependent, carried interest realizations.
HASI is the undisputed, highly profitable financial architect of the United States energy transition, trading at a deeply discounted forward multiple while rapidly accelerating its return on equity, though investors must vigilantly monitor political risks to domestic green subsidies.
H&R Block is a ruthlessly efficient, heavily undervalued cash-compounding machine utilizing monopolistic pricing power to aggressively retire its own stock, though investors must monitor the long-term threat of AI automating complex tax advisory.
Hinge Health is the fundamentally dominant, wildly profitable pioneer of the digital musculoskeletal care revolution, poised to capture immense cross-selling upside through its GI expansion, though investors must monitor the intense competitive pricing threats from well-capitalized rivals like Sword Health.
Hims & Hers is a hyper-growth telehealth disruptor riding the GLP-1 wave, but faces intense margin pressure and existential regulatory threats over drug compounding.
Halozyme is a fundamentally flawless, hyper-profitable royalty machine trading at a deeply distressed valuation, though investors must aggressively navigate the binary, high-stakes legal battle surrounding its core patents against emerging rival Alteogen.
Henry Schein combines dominant distribution scale with an accelerating, high-margin software and specialty product portfolio, offering a compelling long-term compounder at a reasonable valuation despite near-term macroeconomic and consolidation headwinds.
Hut 8 is executing a massive pivot from Bitcoin mining to AI infrastructure, leveraging an 8.3 GW power moat to secure $26.6 billion in hyperscaler leases despite extreme transitionary multiples.
HCI pairs the elite underwriting margins of a dominant Florida insurer with the explosive upside of a billion-dollar InsurTech subsidiary, trading at a deeply compressed single-digit multiple that provides a massive margin of safety against inherent catastrophe risks.